179 related articles for article (PubMed ID: 19236157)
1. Targeting the extracellular signature of metastatic colorectal cancers.
Marchiò S; Arap W; Pasqualini R
Expert Opin Ther Targets; 2009 Mar; 13(3):363-79. PubMed ID: 19236157
[TBL] [Abstract][Full Text] [Related]
2. Methods and assays for specific targeting and delivery of RNA nanoparticles to cancer metastases.
Rychahou P; Shu Y; Haque F; Hu J; Guo P; Evers BM
Methods Mol Biol; 2015; 1297():121-35. PubMed ID: 25896000
[TBL] [Abstract][Full Text] [Related]
3. Engineered nanoparticles for imaging and drug delivery in colorectal cancer.
Pavitra E; Dariya B; Srivani G; Kang SM; Alam A; Sudhir PR; Kamal MA; Raju GSR; Han YK; Lakkakula BVKS; Nagaraju GP; Huh YS
Semin Cancer Biol; 2021 Feb; 69():293-306. PubMed ID: 31260733
[TBL] [Abstract][Full Text] [Related]
4. Current status of nanoscale drug delivery systems for colorectal cancer liver metastasis.
Hong Y; Rao Y
Biomed Pharmacother; 2019 Jun; 114():108764. PubMed ID: 30901717
[TBL] [Abstract][Full Text] [Related]
5. Targeting metastatic colorectal cancer in 2008: a long way from 5-FU.
Pohl A; Zhang W; Ning Y; Manegold PC; Lurje G; Lenz HJ
Oncology (Williston Park); 2008 Apr; 22(4):456-62; discussion 462-3, 467-8, 474 passim. PubMed ID: 18472617
[TBL] [Abstract][Full Text] [Related]
6. Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer.
Wu M; Rivkin A; Pham T
Clin Ther; 2008 Jan; 30(1):14-30. PubMed ID: 18343240
[TBL] [Abstract][Full Text] [Related]
7. Anti-metastatic treatment in colorectal cancer: targeting signaling pathways.
Lemos C; Sack U; Schmid F; Juneja M; Stein U
Curr Pharm Des; 2013; 19(5):841-63. PubMed ID: 22973955
[TBL] [Abstract][Full Text] [Related]
8. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
10. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.
Martini G; Troiani T; Cardone C; Vitiello P; Sforza V; Ciardiello D; Napolitano S; Della Corte CM; Morgillo F; Raucci A; Cuomo A; Selvaggi F; Ciardiello F; Martinelli E
World J Gastroenterol; 2017 Jul; 23(26):4675-4688. PubMed ID: 28765689
[TBL] [Abstract][Full Text] [Related]
11. Suppression of colorectal cancer subcutaneous xenograft and experimental lung metastasis using nanoparticle-mediated drug delivery to tumor neovasculature.
Wang C; Zhao M; Liu YR; Luan X; Guan YY; Lu Q; Yu DH; Bai F; Chen HZ; Fang C
Biomaterials; 2014 Jan; 35(4):1215-26. PubMed ID: 24231414
[TBL] [Abstract][Full Text] [Related]
12. Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.
Strickler JH; Wu C; Bekaii-Saab T
Cancer Treat Rev; 2017 Nov; 60():109-119. PubMed ID: 28946014
[TBL] [Abstract][Full Text] [Related]
13. BRAF in metastatic colorectal cancer: the future starts now.
Orlandi A; Calegari A; Inno A; Berenato R; Caporale M; Niger M; Bossi I; Di Bartolomeo M; de Braud F; Pietrantonio F
Pharmacogenomics; 2015 Dec; 16(18):2069-81. PubMed ID: 26615988
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional and multitargeted nanoparticles for drug delivery to overcome barriers of drug resistance in human cancers.
Dawar S; Singh N; Kanwar RK; Kennedy RL; Veedu RN; Zhou SF; Krishnakumar S; Hazra S; Sasidharan S; Duan W; Kanwar JR
Drug Discov Today; 2013 Dec; 18(23-24):1292-300. PubMed ID: 24055842
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticles for Colorectal Cancer Targeted Drug Delivery and MR Imaging: Current Situation and Perspectives.
Dong Z; Cui MY; Peng Z; Li Y; Wang X; Fang Z; Jiang M; Xu L; Luo Y; Li ZP; Feng ST
Curr Cancer Drug Targets; 2016; 16(6):536-50. PubMed ID: 26632434
[TBL] [Abstract][Full Text] [Related]
17. Optimizing administration of epidermal growth factor receptor-targeted agents in the treatment of colorectal cancer.
Van Cutsem E
Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S60-5. PubMed ID: 18021489
[TBL] [Abstract][Full Text] [Related]
18. Recent achievements in colorectal cancer diagnostic and therapy by the use of nanoparticles.
Bartoş A; Bartoş D; Szabo B; Breazu C; Opincariu I; Mironiuc A; Iancu C
Drug Metab Rev; 2016; 48(1):27-46. PubMed ID: 26828283
[TBL] [Abstract][Full Text] [Related]
19. Nanotechnology a Boon for Colorectal Cancer Treatment.
Kriplani P; Guarve K
Recent Pat Anticancer Drug Discov; 2023; 18(3):379-396. PubMed ID: 36221866
[TBL] [Abstract][Full Text] [Related]
20. Diatom-Based Nanomedicine for Colorectal Cancer Treatment: New Approaches for Old Challenges.
Tramontano C; De Stefano L; Rea I
Mar Drugs; 2023 Apr; 21(5):. PubMed ID: 37233460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
